PLA2G2A and myeloid sarcoma: Regardless of immunomodulation therapy, mean levels of sPLA2 were increased 6-fold in the urine of MS patients in relapses or in the active phase of disease and 4-fold in patients in remission (Cunningham et al., 2006).